Clinical Trials Logo

Dysentery clinical trials

View clinical trials related to Dysentery.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05360940 Recruiting - Clinical trials for Dyspepsia Abdominal Burning Pain Diarrhea Dysentery

Concomitant Infection of Intestinal Parasites and Helicobacter Pylori

Start date: September 2022
Phase:
Study type: Observational

Intestinal parasitic infections such as Giardia lamblia, Entamoeba histolyica and Enterobius Vermicularis are among the most common infections worldwide.So parasitic infections are considered one of the major health problems in the world especially in developing countries. Helicobacter pylori is a gram-negative,helical-shaped,motile bacillus bacterium,which colonizes the gastric mucosa. H.pylori bacterium secretes urease,a special enzyme that converts urea to ammonia. Ammonia reduces the stomach's acidity .This risk factor allows pathogenic intestinal protozoa such as G.lamblia to take the opportunity to cross through the stomach's increased pH and cause disease.

NCT ID: NCT05166850 Recruiting - Cholera Clinical Trials

Preventative Intervention for Cholera for 7 Days

PICHA-7
Start date: December 22, 2021
Phase: N/A
Study type: Interventional

The first objective of our study is to develop a theory-driven evidence-based targeted water, sanitation, and hygiene (WASH) intervention for household members of diarrhea patients in South Kivu, Democratic Republic of the Congo (DRC) through formative research and community engagement. The second objective is to conduct a randomized controlled trial of 2,320 household members of 580 severe diarrhea patients to evaluate the effectiveness of the developed targeted WASH intervention in terms of: 1. reducing diarrheal diseases household members of cholera and severe diarrhea patients; and 2. increasing WASH behaviors.

NCT ID: NCT05156528 Recruiting - Shigellosis Clinical Trials

Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years

Start date: December 11, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, immunogenicity and safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in infants and children aged from 6 months to 5 years.

NCT ID: NCT04759937 Recruiting - Dysentery Amebic Clinical Trials

Immunochromatography Versus Microscopy for Diagnosis of Entamoeba Histolytica/Dispar Infection.

Start date: March 20, 2021
Phase:
Study type: Observational

Amoebiasis, an infection by the protozoan parasite Entamoeba histolytica is globally considered as the third leading parasitic cause of human mortality besides malaria and schistosomiasis. It is estimated that E. histolytica may infect half a billion people annually. Moreover, it was estimated that 100,000 patients per year died due to the clinical complications of the disease. Laboratory diagnosis of E. histolytica/dispar is usually achieved by microscopic detection of trophozoites or cysts in stool samples. Microscopy is time consuming and requires an experienced observer to identify the organism. Furthermore, it must be performed on three stool samples to increase sensitivity leading to decreased patient compliance and delay in the final diagnosis. Therefore, a few the commercially available copro-antigen assay have been developed for E. histolytica/dispar diagnosis including the enzyme immunoassay and non-enzymatic immunochromatographic (ICT) assays that do not depend on microscopy skills and increase laboratory efficiency by reducing time and cost. The aim of the study is: 1. to evaluate the efficacy of commercially available rapid immunochromatographic Copro-antigen assay (RIDA® QUICK Entamoeba) in comparison with conventional microscopic examination for the diagnosis of E. histolytica /dispar infection. 2. to estimate the prevalence of E. histolytica /dispar infection in outpatients in Sohag.